F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: F-18FDG PET/CT and CT.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison of F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer
Overview
Is to compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
Detailed description
* The optimal treatment of non-small cell lung cancer (NSCLC) relies on accurate disease staging that is based on the TNM system which relies on tumor size, regional nodal involvement, and the presence of metastasis. * CT is the standard modality used to assess the intra-thoracic spread but false negative CT scans have been reported and were related to the presence of metastasis in normal sized lymph nodes and false positive findings have been related to lymph node enlargement due to benign process.
PET is most widely used in thoracic oncology because of its superiority over other imaging techniques in staging nodal and metastatic disease, however, the poor anatomic details of PET can lead to errors in diagnosis and staging.
• To solve this problem, CT is combined with PET to provide matched morphological and functional data. The diagnostic capability of PET/CT in the preoperative staging of lung cancer is superior to that of CT alone and PET alone as it has the advantage of a more accurate assignment of tumor stage (T stage) and defining the lymph node stage (N stage) as well as reduction of the number of useless thoracotomies
Interventions
- Device F-18FDG PET/CT and CT
compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
Primary outcome measures
- compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management. [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Patients with pathologically proven NSCLC who underwent initial PET/CT images.
- All patients ≥ 18 years.
Exclusion criteria
- Patients who had started treatment before initial PET/CT. Patients with glucose level < 200 mg/dl. Patients with another malignant condition.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Hadar R, Slonim A, Kuhn J. Role of D-tryptophan oxidase in D-tryptophan utilization by Escherichia coli. J Bacteriol. 1976 Mar;125(3):1096-1104. doi: 10.1128/jb.125.3.1096-1104.1976. PMID 3493
Identifiers
NCT: NCT06789562 · F-18 FDG PET/CTand CT in lung